Exercise and obesity in fibromyalgia: beneficial roles of IGF-1 and resistin?

Jan L Bjersing, Malin Erlandsson, Maria I Bokarewa, Kaisa Mannerkorpi, Jan L Bjersing, Malin Erlandsson, Maria I Bokarewa, Kaisa Mannerkorpi

Abstract

Introduction: Severe fatigue is a major health problem in fibromyalgia (FM). Obesity is common in FM, but the influence of adipokines and growth factors is not clear. The aim was to examine effects of exercise on fatigue, in lean, overweight and obese FM patients.

Methods: In a longitudinal study, 48 FM patients (median 52 years) exercised for 15 weeks. Nine patients were lean (body mass index, BMI 18.5 to 24.9), 26 overweight (BMI 25 to 29.9) and 13 obese. Fatigue was rated on a 0 to 100 mm scale (fibromyalgia impact questionnaire [FIQ] fatigue) and multidimensional fatigue inventory (MFI-20) general fatigue (MFIGF). Higher levels in FIQ fatigue and MFIGF indicate greater degree of fatigue. Free and total IGF-1, neuropeptides, adipokines were determined in serum and cerebrospinal fluid (CSF).

Results: Baseline FIQ fatigue correlated negatively with serum leptin (r=-0.345; P=0.016) and nerve growth factor (NGF; r=-0.412; P=0.037). In lean patients, baseline MFIGF associated negatively with serum resistin (r=-0.694; P=0.038). FIQ Fatigue associated negatively with CSF resistin (r=-0.365; P=0.073). Similarly, FIQ fatigue (r=-0.444; P=0.026) and MFIGF correlated negatively with CSF adiponectin (r=-0.508; P=0.01). In lean patients, FIQ fatigue (P=0.046) decreased after 15 weeks. After 30 weeks, MFIGF decreased significantly in lean (MFIGF: P=0.017), overweight (MFIGF: P=0.001), and obese patients (MFIGF: P=0.016). After 15 weeks, total IGF-1 increased in lean (P=0.043) patients. ∆Total IGF-1 differed significantly between lean and obese patients (P=0.010). ∆Total IGF-1 related negatively with ∆MFIGF after 15 weeks (r=-0.329; P=0.050). After 30 weeks, ∆FIQ fatigue negatively correlated with ∆NGF (r=-0.463; P=0.034) and positively with ∆neuropeptide Y (NPY) (r=0.469; P=0.032). Resistin increased after 30 weeks (P=0.034). ∆MFIGF correlated negatively with ∆resistin (r=-0.346; P=0.031), being strongest in obese patients (r=-0.815; P=0.007). In obese patients, ∆FIQ fatigue after 30 weeks correlated negatively with ∆free IGF-1 (r=-0.711; P=0.032).

Conclusions: Exercise reduced fatigue in all FM patients, this effect was achieved earlier in lean patients. Baseline levels of resistin in both serum and CSF associated negatively with fatigue. Resistin was increased after the exercise period which correlated with decreased fatigue. Changes in IGF-1 indicate similar long-term effects in obese patients. This study shows reduced fatigue after moderate exercise in FM and indicates the involvement of IGF-1 and resistin in these beneficial effects.

Trial registration: ClinicalTrials.gov: NCT00643006.

References

    1. Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med. 2000;160:221–227. doi: 10.1001/archinte.160.2.221.
    1. Mease P, Clauw D, Christensen R, Crofford L, Gendreau R, Martin SA, Simon LS, Strand V, Williams DA, Arnold LM. OMERACT Fibromyalgia Working Group. Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update. J Rheumatol. 2011;38:1487–1495. doi: 10.3899/jrheum.110277.
    1. Staud R. Peripheral and central mechanisms of fatigue in inflammatory and noninflammatory rheumatic diseases. Curr Rheumatol Rep. 2012;14:539–548. doi: 10.1007/s11926-012-0277-z.
    1. Mannerkorpi K, Gard G. Hinders for continued work among persons with fibromyalgia. BMC Muskuloskeletal Disorders. 2012;13:96. doi: 10.1186/1471-2474-13-96.
    1. Nicassio P, Moxham E, Schumand C, Gevirtz R. The contribution of pain, reported sleep quality, and depressive symptoms to fatigue in fibromyalgia. Pain. 2002;100:271–279. doi: 10.1016/S0304-3959(02)00300-7.
    1. Bennet RM, Jones J, Turk DC, Russel IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disorders. 2007;8:27. doi: 10.1186/1471-2474-8-27.
    1. Neumann L, Lerner E, Glazer Y, Bolotin A, Shefer A, Buskila D. A cross-sectional study of the relationship between body mass index and clinical characteristics, tenderness measures, quality of life and physical functioning in fibromyalgia patients. Clin Rheumatol. 2008;27:1543–1547. doi: 10.1007/s10067-008-0966-1.
    1. Okifuji A, Bradshaw DH, Olson C. Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms and functions. Clin Rheumatol. 2009;28:475–478. doi: 10.1007/s10067-009-1094-2.
    1. Kim CH, Luedtke CA, Vincent A, Thompson JM, Oh TH. Association of body mass index with symptom severity and quality of life in patients with fibromyalgia. Arthritis Care Res. 2012;64:222–228.
    1. Mork PJ, Vasseljen O, Nilsen TI. Association between physical exercise, body mass index and risk of fibromyalgi: longitudinal data from the Norwegian Nord-Trondelag Health Study. Arthritis Care Res. 2010;62:611–617. doi: 10.1002/acr.20118.
    1. Okifuji A, Donaldson GW, Barck L, Fine PG. Relationship between fibromyalgia and obesity in pain function, mood and sleep. J Pain. 2010;11:1329–1337. doi: 10.1016/j.jpain.2010.03.006.
    1. Maloney EM, Boneva RS, Lin JM, Reeves WC. Chronic fatigue syndrome is associated with metabolic syndrome: results from a case-control study in Georgia. Metabolism. 2010;59:1351–1357. doi: 10.1016/j.metabol.2009.12.019.
    1. Vahl N, Jørgensen JO, Skjaerbaek C, Veldhuis JD, Orskov H, Christiansen JS. Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults. Am J Physiol. 1997;272:E1108–E1116.
    1. Pijl H, Langendonk JG, Burggraaf J, Frölich M, Cohen AF, Veldhuis JD, Meinders AE. Altered neuroregulation of GH secretion in viscerally obese premenopausal women. J Clin Endocrinol Metab. 2001;86:5509–5515. doi: 10.1210/jc.86.11.5509.
    1. Faupel-Badger JM, Berrigan D, Ballard-Barbash R, Potischman N. Anthropometric corelates of insulin-like growth factor 1 (IGF-1) and IGF-1 binding protein-3 (IGFBP-3) levels by race/ethnicity and gender. Ann Epidemiol. 2009;19:841–849. doi: 10.1016/j.annepidem.2009.08.005.
    1. Friedrich N, Jørgensen T, Juul A, Spielhagen C, NaucK M, Wallaschofski H, Linneberg A. Insulin-like growth factor I and anthropometric parameters in a Danish population. Exp Clin Endocrinol Diabetes. 2012;120:171–174.
    1. Bjersing JL, Dehlin M, Erlandsson M, Bokarewa MI, Mannerkorpi K. Changes in pain and insulin-like growth factor 1 in fibromyalgia during exercise: the involvement of cerebrospinal inflammatory factors and neuropeptides. Arthr Res Ther. 2012;14:R162. doi: 10.1186/ar3902.
    1. Jones KD, Deodhar P, Lorentzen A, Bennett RM, Deodhar AA. Growth hormone perturbations in fibromyalgia: a review. Semin Arthritis Rheum. 2007;36:357–379. doi: 10.1016/j.semarthrit.2006.09.006.
    1. Cuatrecasas G, Alegre C, Fernandez-Sola J, Gonzalez MJ, Garcia-Fructuoso F, Poca-Dias V, Nadal A, Navarro F, Mera A, Lage M, Peino R, Casanueva F, Linan C, Sesmilo G, Coves MJ, Izquierdo JP, Alvarez I, Granados E, Puig- Domingo M. Growth hormone treatment for sustained pain reduction and improvement in quality of life in severe fibromyalgia. Pain. 2012;153:1382–1389. doi: 10.1016/j.pain.2012.02.012.
    1. Garcia-Segura LM, Diz-Chaves Y, Perez-Martin M, Darnaudéry M. Estradiol, insulin-like growth factor-I and brain aging. Psychoneuroendocrinology. 2007;32:S57–S61.
    1. Morgado C, Silva L, Pereira-Terra P, Tavares I. Changes in serotonergic and noradrenergic descending pain pathways during painful diabetic neuropathy: the preventive action of IGF1. Neurobiol Dis. 2011;43:275–284. doi: 10.1016/j.nbd.2011.04.001.
    1. Arwert LI, Veltman DJ, Deijen JB, van Dam PS, Delemarre-van deWaal HA, Drent ML. Growth hormone deficiency and memory functioning in adults visualized by functional magnetic resonance imaging. Neuroendocrinology. 2005;82:32–40. doi: 10.1159/000090123.
    1. Thundyil J, Pavloski D, Sobey CG, Arumugam TV. Adiponectin receptor signalling in the brain. Br J Pharmacol. 2012;165:313–327. doi: 10.1111/j.1476-5381.2011.01560.x.
    1. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Medicine. 2002;8:1288–1295. doi: 10.1038/nm788.
    1. Bassi M, do Carmo JM, Hall JE, da Silva AA. Chronic effects of centrally administered adiponectin on appetite, metabolism and blood pressure regulation in normotensive and hypertensive rats. Peptides. 2012;37:1–5. doi: 10.1016/j.peptides.2012.06.013.
    1. Hoyda TD, Samson WK, Ferguson AV. Adiponectin depolarizes parvocellular paraventricular nucleus neurons controlling neuroendocrine and autonomic function. Endocrinology. 2009;150:832–840.
    1. Barbosa IG, Rocha NP, de Miranda AS, Magalhaes PV, Huguet RB, de Souza LP, Kapczinski F, Teixeira AL. Increased levels of adipokines in bipolar disorder. J Psychiatr Res. 2012;46:389–393. doi: 10.1016/j.jpsychires.2011.11.010.
    1. Diniz BS, Teixeira AL, Campos AC, Miranda AS, Rocha NP, Talib LL, Gattaz WF, Forlenza OV. Reduced serum levels of adiponectin in elderly patients with major depression. J Psychiatr Res. 2012;46:1081–1085. doi: 10.1016/j.jpsychires.2012.04.028.
    1. Liu J, Guo M, Zhang D, Cheng S-Y, Liu M, Ding J, Scherer PE, Liu F, and Xin-Yun Lu. Adiponectin is critical in determining susceptibility to depressive behaviors and has antidepressant-like activity. Proc Natl Acad Sci USA. 2012;109:12248–12253. doi: 10.1073/pnas.1202835109.
    1. Schwartz DR, Lazar MA. Human resistin: found in translation from mouse to man. Trends Endocrinol Metab. 2011;22:259–265.
    1. Krysiak R. The role of adipokines in connective tissue diseases. Eur J Nutr. 2012;51:513–528. doi: 10.1007/s00394-012-0370-0.
    1. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun. 2003;300:472–476. doi: 10.1016/S0006-291X(02)02841-3.
    1. Nagaev I, Bokarewa M, Tarkowski A, Smith U. Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes. PLoS One. 2006;1:e31. doi: 10.1371/journal.pone.0000031.
    1. Kusminski CM, Scherer PE. The road from discovery to clinic: adiponectin as a biomarker of metabolic status. Nature. 2009;86:592–595.
    1. Lau CH, Muniandy S. Novel adiponectin-resistin (AR) and insulin resistance (IRAR) indexes are useful integrated diagnostic biomarkers for insulin resistance, type 2 diabetes and metabolic syndrome: a case control study. Cardiovascular Diabetology. 2011;10:8. doi: 10.1186/1475-2840-10-8.
    1. Tarkowski A, Bjersing J, Shestakov A, Bokarewa MI. Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. J Cell Mol Med. 2010;14:1419–1431.
    1. Boström EA, Svensson M, Andersson S, Jonsson I-M, Ekwall A-K H, Eisler T, Dahlberg LE, Smith U, Bokarewa MI. Resistin and insulin/insulin-like growth factor signaling in rheumatoid arthritis. Arthritis Rheum. 2011;63:2894–2904. doi: 10.1002/art.30527.
    1. Zhang Y, Proenca P, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425–432. doi: 10.1038/372425a0.
    1. Kamohara S, Burcelin R, Halaas JL, Friedman JM, Charron MJ. Acute stimulation of glucose metabolism in mice by leptin treatment. Nature. 1997;389:374–377. doi: 10.1038/38717.
    1. Chehab FF. Leptin as a regulator of adipose mass and reproduction. Trends Pharmacol Sci. 2000;21:309–314. doi: 10.1016/S0165-6147(00)01514-5.
    1. Lu XY, Kim CS, Frazer A, Zhang W. Leptin: a potential novel antidepressant. Proc Natl Acad Sci USA. 2006;103:1593–1598. doi: 10.1073/pnas.0508901103.
    1. Liu J, Garza JC, Bronner J, Kim CS, Zhang W, Lu XY. Acute administration of leptin produces anxiolytic-like effects: a comparison with fluoxetine. Psychopharmacology. 2010;207:535–545. doi: 10.1007/s00213-009-1684-3.
    1. Satoh N, Ogawa Y, Katsuura G, Tsuji T, Masuzaki H, Hiraoka J, Okazaki T, Tamaki M, Hayase M, Yoshimasa Y, Nishi S, Hosoda K, Nakao K. Pathophysiological significance of the obese gene product, leptin, in ventromedial hypothalamus (VMH)-lesioned rats: evidence for loss of its satiety effect in VMH-lesioned rats. Endocrinology. 1997;138:947–954. doi: 10.1210/en.138.3.947.
    1. Delgado TC, Violante IR, Nieto-Charques L, Cerdan S. Neuroglial metabolic compartmentation underlying leptin deficiency in the obese ob/ob mice as detected by magnetic resonance imaging and spectroscopy methods. Journal of Cerebral Blood Flow & Metabolism. 2011;31:2257–2266. doi: 10.1038/jcbfm.2011.134.
    1. Gao S, Zhu G, Gao X, Wu D, Carrasco P, Casals N, Hegardt FG, Moran TH, Lopaschuk GD. Important roles of brain-specific carnitine palmitoyltransferase and ceramide metabolism in leptin hypothalamic control of feeding. Proc Natl Acad Sci USA. 2011;108:9691–9696. doi: 10.1073/pnas.1103267108.
    1. Stephens TW, Basinski M, Bristow PK, Bue-Valleskey JM, Burgett SG, Craft L, Hale J, Hoffmann J, Hsiung HM, Kriauciunas A. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature. 1995;377:530–532. doi: 10.1038/377530a0.
    1. Haque Z, Akbar N, Yasmeen F, Haleem MA, Haleem DJ. Inhibition of Immobilization Stress-induced Anorexia, Behavioral Deficits and Plasma Corticosterone Secretion by Injected Leptin in Rats. Stress. 2012. doi:10.3109/10253890.2012.73604.
    1. Guo M, Huang TY, Garza JC, Chua SC, Lu XY. Selective deletion of leptin receptors in adult hippocampus induces depression-related behaviours. Int J Neuropsychopharmacol. 2012;29:1–11.
    1. Maeda T, Kiguchi N, Kobayashi Y, Ikuta T, Ozaki M, Kishioka S. Leptin derived from adipocytes in injured peripheral nerves facilitates development of neuropathic pain via macrophage stimulation. Proc Natl Acad Sci USA. 2009;106:13076–13081. doi: 10.1073/pnas.0903524106.
    1. Malva JO, Xapelli S, Baptista S, Valero J, Agasse F, Ferreira R, Silva AP. Multifaces of neuropeptide Y in the brain - neuroprotection, neurogenesis and neuroinflammation. Neuropeptides. 2012;46:299–308. doi: 10.1016/j.npep.2012.09.001.
    1. Anderberg UM, Liu Z, Berglund L, Nyberg F. Elevated plasma levels of neuropeptide Y in female fibromyalgia patients. Eur J Pain. 1999;3:19–30. doi: 10.1016/S1090-3801(99)90185-4.
    1. Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, Sternberg EM, Gold PW, Chrousos GP, Wilder RL. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum. 1994;37:1583–1592. doi: 10.1002/art.1780371105.
    1. Di Franco M, Iannuccelli C, Alessandri C, Paradiso M, Riccieri V, Libri F, Valesini G. Autonomic dysfunction and neuropeptide Y in fibromyalgia. Clin Exp Rheumatol. 2009;27:S75–78.
    1. Griep EN, Boersma JW, Lentjes EG, Prins AP, van der Korst JK, de Kloet ER. Function of the hypothalamic-pituitary-adrenal axis in patients with fibromyalgia and low back pain. J Rheumatol. 1998;25:1374–1381.
    1. Fletcher MA, Rosenthal M, Antoni M, Ironson G, Zeng XR, Barnes Z, Harvey JM, Hurwitz B, Levis S, Broderick G, Klimas NG. Plasma neuropeptide Y: a biomarker for symptom severity in chronic fatigue syndrome. Behav Brain Funct. 2010;6:76. doi: 10.1186/1744-9081-6-76.
    1. Klimas NG, Broderick G, Fletcher MA. Biomarkers for chronic fatigue. Brain, Behaviour, and Immunity. 2012;26:1202–1210. doi: 10.1016/j.bbi.2012.06.006.
    1. Irwin MR. Human psychoneuroimmunology: 20 years of discovery. Brain behav. 2008;22:129–139.
    1. Russel IJ, Orr MD, Litman B, Vipraio GA, Alboukrek D, Michalek JE, Lopez Y, MacKillip F. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 1994;37:1593–1601. doi: 10.1002/art.1780371106.
    1. Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomen in patients with fibromyalgi: new features for diagnosis. Pain. 1988;32:21–26. doi: 10.1016/0304-3959(88)90019-X.
    1. Liu Z, Welin M, Bragee B, Nyberg F. A high-recovery extraction procedure for quantitative analysis of substance P and opioid peptides in human cerebrospinal fluid. Peptides. 2000;21:853–860. doi: 10.1016/S0196-9781(00)00219-9.
    1. Giovengo SL, Russel IJ, Larson AA. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol. 1999;26:1564–1569.
    1. Kadetoff D, Lampa J, Westman M, Andersson M, Kosek E. Evidence of central inflammation in fibromyalgia - increased cerebrospinal fluid interleukin-8 levels. J Neuroimmunol. 2012;242:33–38. doi: 10.1016/j.jneuroim.2011.10.013.
    1. Mannerkorpi K, Nordeman L, Cider Å, Jonsson G. Does moderate-to-high aerobic exercise result in better improvement of body impairments and pain than low-intensive exercise in FM? A prospective randomised controlled trial. Arthritis Res Ther. 2010;12:R189. doi: 10.1186/ar3159.
    1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtner JJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain GA, Reynolds WJ, Romano TJ, Russell IJ, Sheon RP. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160–172. doi: 10.1002/art.1780330203.
    1. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol. 1991;18:728–733.
    1. Ericsson A, Mannerkorpi K. Assessment of fatigue in patients with fibromyalgia and chronic widespread pain. Reliability and validity of the Swedish version of the MFI-20. Disabil Rehabil. 2007;30:1665–1670.
    1. Srikuea R, Symons TB, Long DE, Lee JD, Shang Y, Chomentowski PJ, Yu G, Crofford LJ, Peterson CA. Fibromyalgia is associated with altered skeletal muscle characteristics which may contribute to post-exertional fatigue in post-menopausal women. Arthritis Rheum. 2012;65:519–528.
    1. Carville S, Arendt-Nielsen S, Bliddal H, Blotman F, Branco JC, Buskila D, Da Silva JA, Danneskiold-Samsøe B, Dincer F, Henriksson C, Henriksson KG, Kosek E, Longley K, McCarthy GM, Perrot S, Puszczewicz M, Sarzi-Puttini P, Silman A, Späth M, Choy EH; EULAR. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Annals Rheum Dis. 2008;67:536–541.
    1. Mannerkorpi K, Nordeman L, Ericsson A, Arndorw M. GAU-Study-Group. Pool-exercise for patients with fibromyalgia or chronic widespread pain. A randomized controlled trial and subgroup analyses. J Rehabil Med. 2009;41:751–760. doi: 10.2340/16501977-0409.
    1. Kim CH, Luedtke CA, Vincent A, Thompson JM, Oh TH. Association of body mass index with symptom severity and quality of life in patients with fibromyalgia. Arthritis Care Res. 2012;64:222–228.
    1. Mork PJ, Vasseljen O, Nilsen TI. Association between physical exercise, body mass index and risk of fibromyalgi: longitudinal data from the Norwegian Nord-Trondelag Health Study. Arthritis Care Res. 2010;62:611–617. doi: 10.1002/acr.20118.
    1. Choy E, Arnold L, Clauw D, Crofford L, Glass J, Simon L, Martin SA, Strand CV, Williams DA, Mease PJ. Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol. 2009;36:2330–2334. doi: 10.3899/jrheum.090368.
    1. Bennett RM. Adult growth hormone deficiency in patients with fibromyalgia. Curr Rheumatol Rep. 2002;4:306–312. doi: 10.1007/s11926-002-0039-4.
    1. Kohno D, Yada T. Neuropeptides. Arcuate NPY neurons sense and integrate peripheral metabolic signals to control feeding. Neuropeptides. 2012;46:315–319. doi: 10.1016/j.npep.2012.09.004.
    1. Garcia-Segura LM, Rodriguez JR, Torres-Aleman I. Localization of the insuli-like growth factor I receptor in the cerebellum and hypothalamus of adult rats: an electron microscopic study. J Neurocytology. 1997;26:479–490. doi: 10.1023/A:1018581407804.
    1. Fernandez-Galas MC, Naftolin F, Garcia-Segura LM. Phasic synaptic remodeling of the rat arcuate nucleus during the estrous cycle depends on insulin-like growth factor-I receptor activation. J Neurosci Res. 1999;55:286–292. doi: 10.1002/(SICI)1097-4547(19990201)55:3<286::AID-JNR3>;2-4.
    1. Singhal NS, Lazar MA, Ahima RS. Central resistin induces insulin resistance via neuropeptide Y. J Neurosci. 2007;27:12924–12932. doi: 10.1523/JNEUROSCI.2443-07.2007.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir